EFTA01462124.pdf

From: Tazia Smith Sent: To: CC: ; Vahe Stepanian J; Matt Glassman Subject: Attachments: pic12199.gif; pic24071.gif Classification: Confidential Good Morning Rich - As you saw, Fma reported Q2 EPs of ($0.49) vs ($0.48) consensus. The company beat on the topline with 514.5m of Q2 revenues (vs 413.4m cons) and boasted 263% yoy growth in clinical tests (5,908). The company reiterated it's full year guidance, which was at the low-end vs. consensus: 552-58M FY Rev guidance vs S58.0M cons, and clinical tests in the range of 22k-25k for full-year. As you know, DB doesn't cover the name, but competitors have published this morning and broadly reiterated netural to bullish outlooks, 528-48 price targets. one competitor lowers its target to S31 (from S33), but suggests guidance is reasonable, leadership in clinical data, catalysts including NY state approval, and long-term plans for new capabilities that should broaden the company's overall platform. The stock opens this morning at 524.02 vs a $25.65, on very very light volume, trying to find it's footing post yesterday's gains. Recall that the company is scheduled to present today at 12:45 ET in NYC at an industry conference. Best Regards, Tazia Source: Streetaccount, Bloomberg, 8/13/14. (Embedded image moved to file: pic12199.gif) Tazia smith Director I Key Client Partners - US DB securities Inc Deutsche Asset & wealth Management 345 Park Avenue, 10154-0004 New York, NY, USA Tel. +1(212)454-2889 Fax +1(646)257-3131 Mobile +1 (917)327-4107 Email [email protected] (Embedded image moved to file: pic24071.gif) CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0124507 CONFIDENTIAL SDNY_GM_00270691 EFTA01462124